Shares of Sangamo BioSciences (SGMO) jump 5.5% higher premarket after the firm announces results...


Shares of Sangamo BioSciences (SGMO) jump 5.5% higher premarket after the firm announces results from a Phase 1 clinical program to develop a HIV/AIDS therapeutic treatment. "The data obtained in our treatment interruption studies are very exciting and represent significant progress toward a 'functional cure' for HIV/AIDS."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs